Business Context and Reporting Period
This Form 8-K filing by BioRestorative Therapies, Inc. covers events occurring between June 3, 2019, and June 7, 2019, with a report date of June 6, 2019. The filing details unregistered sales of equity securities and the issuance of convertible promissory notes.
Key Financial Metrics and Transactions
- Debt-for-Equity Swap: Issued 581,092 shares of common stock to settle $105,101 of outstanding indebtedness (including accrued interest).
- Convertible Notes Issuance: Issued notes with a principal amount of $536,950 for cash proceeds of $510,000.
- Interest Rates: Notes bear interest between 8% and 12% per annum.
- Maturity Dates: Range from December 2019 to June 2020.
- Equity for Services: Issued 75,000 shares of immediately vested common stock to a consultant.
Material Changes and Conversion Terms
The filing reports significant changes in capital structure through the issuance of new debt and equity. The convertible notes feature specific conversion mechanics:
- $100,000 Principal Portion: Convertible after 180 days at approximately 58% of the fair value of common stock.
- $436,950 Principal Portion: Convertible at a fixed price of $1.00 or $2.00 per share for the first six months. Thereafter, conversion is at 58% or 65% of fair value.
The filing text does not provide clear values for revenue, operating profit, cash flow, or overall liquidity positions beyond the specific transaction proceeds noted above.
Guidance, Risks, and Unusual Items
The Company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for these transactions, asserting they were not public offerings and were made to accredited investors without general solicitation. No forward-looking guidance or management commentary regarding future financial performance is included in this specific filing.
Investor Verification Checklist
- Verify the dilution impact of the 581,092 shares issued for debt and the 75,000 shares issued for services.
- Confirm the total outstanding principal of convertible notes and the potential dilution if converted at the 58% discount rate.
- Review the Company's cash position to assess the ability to service the $536,950 in new debt if not converted.
- Check subsequent filings for the fair value of common stock used to calculate conversion prices.